Albin from France

Registered at the short selling broker Prime XBT, 2 minutes ago.

» Try Prime XBT you too
Don't show again

Takeda Pharmaceutical Co., Ltd (TAK) shares information

Takeda Pharmaceutical Co – ADR


24h Change

0.36 %

TAK

Live rate: Market closed

Stock data per Friday 1 Jul, 2022

TAK
NEW YORK STOCK EXCHANGE INC.
14.04
13.92
14.09
0.05 (+ 0.36%)
US Market is closed

Live Stock price in graph for Takeda Pharmaceutical Co – ADR (TAK)

  • Latest Volume

    2,174,812 (-9.24 %)

  • Volume prev. day

    2,396,155

  • Avg. daily volume

    2,854,722

  • Market cap

    44,587,876,155

  • P/E ratio

    23.59

  • Today high

    14.11 USD

  • Today low

    13.91 USD

  • 52 week high

    16.52 USD

  • 52 week low

    12.88 USD

  • YTD Change

    + 6.08 %

Quick links

 

Latest news about Takeda Pharmaceutical Co – ADR

Below you can find the most recent news posts about Takeda Pharmaceutical Co – ADR, primarily from US and UK based news sources.

Takeda”s Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years

Friday, 1 July 2022, 16:28:49
Takeda Pharmaceutical Co Ltd (NYSE: TAK ) announced late-breaking data from the Phase 3 SPRING study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2022. The data demonstrated positive results of Takhzyro (lanadelumab) for preventing hereditary angioedema (HAE) attacks in patients 2 to … Full story available on Benzinga.com
— Benzinga


Takeda’s TAKHZYRO (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years

Friday, 1 July 2022, 00:01:00
Takeda (TSE:4502/NYSE:TAK) today announced late-breaking data from the Phase 3 SPRING study (NCT04070326) presented at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022, demonstrating positive results of TAKHZYRO (lanadelumab) for preventing hereditary angioedema (HAE) attacks in patients 2 to <12 years of age, which were consistent with earlier studies in adult
— Wallstreet:Online


Takeda’s TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years

Friday, 1 July 2022, 00:01:00
OSAKA, Japan & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Takeda (TSE:4502/NYSE:TAK) today announced late-breaking data from the Phase 3 SPRING study (NCT04070326) presented at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022, demonstrating positive results of TAKHZYRO® (lanadelumab) for preventing hereditary angioedema (HAE) attacks in patients 2 to <12 years of age, which were consistent with earlier studies in adult and adolescent patients.1 There are currently
— Business Wire


Takeda to absorb unit Nihon”s business assets

Friday, 24 June 2022, 13:12:35
Takeda Pharmaceutical (TAK) said it will succeed to the rights and obligations related to research, development and manufacturing businesses of Plasma-Derived Therapies and other…
— Seeking Alpha


Takeda and Nintendo among Japanese firms quietly celebrating weak yen

Friday, 17 June 2022, 08:16:20
For Takeda Pharmaceutical, Japan”s biggest drugmaker, a weaker yen helps because 80% of its sales are overseas, said the firm”s CFO.
— The Japan Times


Trading broker recommendation

We recommend that you check out Capital.com as they have a very good selection of stocks available for both going short and long.

Rating: 9.57/10
Minimum deposit: €250 by bank
Description: Capital.com offer a large number of stocks for trading. Register an account today and check if they have TAK available or trade one of the many other CFD stocks they have.
Risk warning: 67.7% of retail investor accounts lose money when trading CFDs with Capital.